Why does lamotrigine (Lamictal) cause obsessive‑compulsive disorder?

Lamotrigine Does Not Cause OCD—It May Trigger or Worsen Obsessive-Compulsive Symptoms in Susceptible Individuals

Lamotrigine (Lamictal) does not cause obsessive-compulsive disorder de novo, but rather can induce obsessive-compulsive symptoms in certain patients with bipolar disorder or epilepsy, likely through its effects on glutamatergic neurotransmission and striatal dopamine regulation. This is a medication-induced phenomenon distinct from primary OCD, and symptoms typically resolve within weeks of discontinuation 1.

Mechanism of Symptom Induction

The emergence of obsessive-compulsive symptoms with lamotrigine appears related to:

• Glutamatergic modulation: Lamotrigine inhibits presynaptic glutamate release, which may dysregulate cortico-striatal circuits involved in repetitive behaviors 2, 3
• Dopamine uptake alterations: Changes in striatal dopamine handling may contribute to obsessionality in vulnerable populations 2
• Temporal relationship: Symptoms emerge 2-8 months after lamotrigine initiation or dose escalation, not as primary OCD 1

Clinical Presentation

When lamotrigine induces obsessive-compulsive symptoms, the pattern includes:

• Intrusive, repetitive phrases: A characteristic form of obsessionality reported specifically with lamotrigine, featuring recurrent intrusive phrases rather than typical OCD themes 3
• Dose-dependent relationship: Symptoms often emerge after dose increases (e.g., to 100 mg/day) and improve with dose reduction 2
• Reversibility: In most cases, symptoms resolve within one month of lamotrigine discontinuation 1
• Rechallenge phenomenon: Symptoms recur with lamotrigine reintroduction or dose escalation 3

Population at Risk

Certain patient groups appear more vulnerable:

• Bipolar disorder patients: Multiple case reports document de novo obsessive-compulsive symptoms in bipolar II disorder patients after lamotrigine initiation 1, 2, 3
• Epilepsy patients: Lamotrigine use was independently associated with higher obsessive-compulsive symptom scores in adults with epilepsy, particularly those with temporal lobe seizures 4
• Pre-existing vulnerability: Patients with bipolar disorder may have underlying susceptibility to obsessionality that lamotrigine unmasks 3

Important Clinical Distinction

This is medication-induced obsessive-compulsive symptomatology, not true OCD causation. The FDA label for lamotrigine does not list OCD as an adverse effect 5. The DSM-5 diagnostic hierarchy specifically excludes obsessions and compulsions attributable to the physiological effects of a medication from an OCD diagnosis 6.

Paradoxical Therapeutic Role

Importantly, lamotrigine also serves as a treatment option for OCD:

• Glutamatergic augmentation: Lamotrigine is evaluated as an augmentation agent for treatment-resistant OCD when added to SSRIs 6
• Evidence of efficacy: Recent network meta-analyses show lamotrigine produces significant YBOCS score reduction (MD: -6; 95% CrI: -12, -0.47) with moderate certainty of evidence 7
• Clinical recommendations: Lamotrigine ranks among the most supported augmentation agents for OCD partially responsive to serotonin reuptake inhibitors 8, 7
• Successful case reports: Lamotrigine has been used successfully as monotherapy for bipolar depression with comorbid OCD 9 and as augmentation in severe OCD 10

Management Approach

When obsessive-compulsive symptoms emerge during lamotrigine treatment:

1. Assess temporal relationship: Confirm symptom onset occurred after lamotrigine initiation or dose increase 1
2. Consider dose reduction: Lower the lamotrigine dose as initial intervention 2
3. Discontinue if necessary: Stop lamotrigine if symptoms are severe or persist despite dose reduction 1
4. Monitor for resolution: Expect symptom improvement within one month of discontinuation 1
5. Avoid rechallenge: Do not restart lamotrigine in patients who developed significant obsessive-compulsive symptoms 3

Clinical Caveats

• Limited evidence base: Most data derives from case reports and small observational studies; controlled trials are lacking 11
• Individual variability: The mechanism explaining why only some patients develop obsessionality remains unclear 2
• Confounding factors: Epilepsy severity and temporal lobe involvement independently associate with obsessive-compulsive symptoms, complicating attribution 4
• Bipolar-specific phenomenon: The association appears strongest in bipolar disorder populations, particularly bipolar II 1, 3